Background and objectives Vitamin D deficiency is endemic in children with CKD. We sought to investigate the association of genetic disposition, environmental factors, vitamin D supplementation, and renal function on vitamin D status in children with CKD. 
Introduction
Vitamin D status depends on environmental and endogenous factors and affects a multitude of physiologic processes, such as bone mineral metabolism, the immune system, muscle metabolism, and the cardiovascular phenotype (1) (2) (3) . Although insufficient vitamin D levels are found in a significant proportion of the general pediatric population (4) (5) (6) , vitamin D deficiency seems even more common in children with CKD (7-11) and has not declined over the past few decades (8) . Vitamin D from nutritional intake and dermal synthesis is converted to 25-hydroxy-vitamin D [25(OH)D] in the liver. Although 1,25-dihydroxy-vitamin D [1, 25(OH) 2 D] can be produced by a variety of tissues, the processing to the active form by 1a-hydroxylase mainly takes place in the kidneys (12) . The latter step is controlled by endocrine pathways; in particular, 1a-hydroxylase is activated by parathyroid hormone and inhibited by c-terminal fibroblast growth factor 23, calcium, and phosphorus (13 (12, 14) .
Recent genome-wide association studies have uncovered associations of vitamin D levels with proteins involved in the synthesis, transport, and metabolism of 25(OH)D: 7-dehydrocholesterol reductase (DCHR7), an enzyme reducing the vitamin D 3 precursor 7-dehydroxycholesterol to cholesterol; 25-hydroxylase (CYP2R1), the enzyme converting vitamin D 3 to 25(OH)D; and vitamin D binding protein (DBP or GC) (15) . Single-nucleotide polymorphisms (SNPs) in the genes encoding for DHCR7, CYP2R1, and DBP have been linked to vitamin D deficiency in the general population (15, 16) and the risk of developing vitamin D deficiency-associated diseases, including bone fractures (17) , malignancy (18) , and autoimmune disease (19) .
In this study, we comprehensively analyzed the status of vitamin D metabolites in the largest pediatric CKD cohort studied to date, encompassing a wide variation of geographic distribution, nutritional and cultural habits, and vitamin D supplementation practices. Our study focused on the interaction of genetic and environmental factors in the setting of CKD.
Materials and Methods

Patients and Study Design
Vitamin D metabolite levels [25(OH)D, 1,25(OH) 2 D, and 24,25(OH) 2 D] were measured in children and adolescents between 6 and 18 years old with CKD stage 3-5 before dialysis or transplantation. All patients were participants of the observational Cardiovascular Comorbidity in Children with Chronic Kidney Disease Study and enrolled at 55 pediatric nephrology centers in 12 European countries (20) . Only patients with a complete vitamin D status and genetic information were included in this cross-sectional analysis. By these criteria, 500 of 704 active patients at the baseline visit were eligible for analysis. The study was approved by all local ethical committees and has been performed in accordance with the principles of the Helsinki Declaration. Written informed consent was given by the parents and adolescents, and oral assent was given by younger children.
For this study, clinical information and biospecimens collected at study entry (between September of 2009 and July of 2011) were analyzed.
Documentation and Definitions
The primary renal diagnoses were categorized as congenital anomalies of the kidneys and urinary tract, glomerulopathies, CKD after AKI, inflammatory disorders, metabolic disorders, and other or unknown The GFR was estimated according to the Schwartz equation on the basis of serum creatinine, cystatin C, and urea (21) , and patients were categorized to CKD stages 3a, 3b, 4, and 5 by eGFR ranges of 45-60, 30-44, 15-29, and ,15 ml/min per 1.73 m 2 , respectively.
Genome-wide SNP genotyping was performed by hybridization on Illumina 2.5M Omni chips, with subsequent imputation to 10 million SNPs. Imputation was performed using the public 1000 Genomes data as a reference panel (22, 23) . For this study, SNPs associated with vitamin D insufficiency in the general population were used as candidate SNPs (15, 16, 24) A detailed medication history was recorded, including the dosage and application modality of vitamin D. Cholecalciferol or ergocalciferol was used for nutritional vitamin D supplementation, and calcitriol, 1-a-calcidiol, or paricalcitol was used as the active vitamin D analog. Patients were considered as vitamin D supplemented if treatment had started at least 1 week before blood sampling.
Regional solar irradiation was estimated from sunlight radiation maps (www.solargis.info) according to geographic location. Season was classified as winter for November through April and summer for May through October according to the month of blood and urine collection. Patient history was recorded, and a physical examination at the time of blood sampling was performed for anthropometry measurements and pubertal status. Vitamin D status was classified as replete with serum 25(OH)D level .30 ng/ml, insufficient at 16-30 ng/ml, deficient at 5-15.9 ng/ml, and severely deficient at ,5 ng/ml in accordance with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (25) .
Laboratory Techniques
All biochemical analyses were performed centrally. Standard laboratory techniques were used to measure the serum and urinary concentrations of albumin, creatinine, phosphate, and calcium. Intact parathyroid hormone (iPTH) was measured with the Elecsys ECLIA (Roche Diagnostics, Indianapolis, IN), and C-terminal c-terminal fibroblast growth factor was measured with the Immutopics ELISA (San Clemente). Vitamin D metabolites were measured via liquid chromatography-mass spectrometry/mass spectrometry using an Acquity UPLC coupled to a Quattro Premier Mass Spectrometer (Waters, Milford, MA) as described by Aronov et al. (26) . The lower limit of quantification was 25 pg/ml for all vitamin D metabolites. The interassay and intra-assay coefficients of variation were #25%.
Statistical Analyses
Serum levels of 25(OH)D and 24,25(OH) 2 D were below the detection limit (DL) in very few samples, for which concentration was assumed to be DL= ffiffi ffi 2 p . For 1,25(OH) 2 D, approximately 30% of values were below the DL and handled using the distribution-based multiple imputation method (27) . Imputation yielded five complete datasets; these were analyzed separately, and the results were pooled. The influence of potential environmental and disease-associated covariates on vitamin D status was analyzed using multivariable linear regression modeling of log-transformed vitamin D levels. Backward variable selection was performed with a threshold of P=0.15.The influence of genetic polymorphisms on vitamin D levels was tested on the basis of the reduced models. The interaction between albuminuria and glomerulopathy on vitamin D levels was tested in multivariate analysis.
Group comparisons were carried out using chi-squared, t, or Mann-Whitney tests in the case of two groups and chisquared test, ANOVA, or Kruskal-Wallis test in the case of more than two groups as appropriate. For seasonal and geographic differences, nonparametric Hodges-Lehmann estimators with corresponding 95% confidence intervals were calculated. Descriptive P values ,0.05 were considered statistically significant. Data were analyzed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC).
Results
Patient Characteristics
Patient characteristics are given in Table 1 . Mean age was 12 years old. Ethnicity was white in 94.6% of the patients. Renal hypodysplasia was the underlying diagnosis in 69.4% of patients, glomerulopathies were the underlying diagnosis in 7.6%, tubulointerstitial and metabolic disorders were the underlying diagnosis in 12%, CKD after AKI was the underlying diagnosis in 4%, and other diagnoses were the underlying diagnosis in 7%. The most common glomerulopathy was FSGS (n=16) followed by rapid progressive GN (n=4) and IgA nephropathy (n=4). Blood samples were obtained in the winter season in 57% of the patients. Annual local solar irradiation at the place of residence was ,1200 kW/m 2 in 25.0%, 1200-1600 kW/m 2 in 40.4%, and .1600 kW/m 2 in 34.6% of patients. Age, radiation, and the season of blood sampling were distributed similarly across CKD stages. The genotype frequency distribution of the selected SNPs in DHCR7, GC, CYP2R1, and CYP24A1 is given in Table 2 .
Vitamin D Metabolite Concentrations
Descriptive statistics of the vitamin D metabolite concentrations are given in Tables 1 and 2 and by region of origin in Supplemental Table 1 
Vitamin D Supplementation
Oral vitamin D supplements were administered in 11.2% of all patients at a median daily dose of 1000 IU/m 2 body surface area. Vitamin D supplementation prevalence increased with declining eGFR from 5.4% in CKD stage 3a to 22.2% in CKD stage 5. In the vitamin D-replete group, 41.4% of patients were vitamin D supplemented compared with 21.5% in the insufficient group and 4.7% in the deficient group. Vitamin D supplementation was associated with twofold higher 25(OH)D (P,0.001) and almost threefold higher 24,25(OH) 2 D levels (P,0.001) ( 
Seasonal and Geographic Factors
25(OH)D levels from blood samples collected in the winter were a median of 4.8 ng/ml lower (95% confidence interval, 3.5 to 6.1) compared with those in the summer season. Among nonsupplemented patients, children in regions with solar radiation .1600 kW/m 2 per year showed in median 3.8 ng/ml lower 25(OH)D levels compared with those in regions with lower sunlight intensity (95% confidence interval, 25.2 to 22.5; P,0.001) in univariate analysis. In this regard, analysis of 25(OH)D levels by treatment center revealed a highly significant inverse (Table 2 ) (P,0.001). During summer time, nonsupplemented Turkish boys had significantly higher 25(OH)D levels than nonsupplemented Turkish girls, whereas no sex difference was observed in children from the other European regions. During wintertime, no sex differences were evident in any region. In the multivariate analysis of the total cohort, the lower 25(OH)D and 24,25(OH) 2 D levels of Turkish patients seemed independent of vitamin D supplementation, solar radiation, season, and underlying renal disease.
Renal Diagnosis and Function
25(OH)D levels were significantly lower in patients with glomerulopathies compared with in patients with other diagnoses (P,0.001) ( Table 2) . This difference was confirmed in the multivariate analysis [ 
Endocrine Factors
By univariate analysis, 25(OH)D and 24,25(OH) 2 D were negatively associated with iPTH (r=20.24; P,0.001 and r=20.3; P,0.001, respectively) but not with c-terminal fibroblast growth factor (cFGF23). In the multivariable regression, iPTH was associated with lower 24,25(OH) 2 D levels, and cFGF23 was associated with higher 24,25(OH) 2 D levels [ Table 3 , correlates of serum 24,25(OH) 2 D concentration, Supplemental Table 3 , full model].
Genetic Variants
Vitamin D levels by genetic polymorphisms of the whole cohort are listed descriptively in Table 2 , genetic correlates, and another subdivision by region of origin is shown in Supplemental Table 1 . Among the variants selected for multivariable analysis in CYP2R1, CYP24A1, GC, and DHCR7, only polymorphisms in the GC gene exhibited a 
Discussion
This study provides a comprehensive analysis of modifiable and nonmodifiable correlates of the vitamin D status of children with CKD. The study cohort covered a large geographic area with substantial variation of climatic conditions, ethnic composition, nutritional and cultural attitudes, and health care policies. To our knowledge, our study is the first to address the role of common variants in vitamin D-regulating genes on vitamin D status in patients with CKD.
Our study across 55 pediatric nephrology centers impressively shows the high current prevalence of vitamin D deficiency in the European pediatric CKD population. Only one in 17 children had a 25(OH)D level considered optimal according to the KDOQI definition (25) , and two thirds of the cohort were classified as deficient. Our findings confirm previous reports of the prevalence of vitamin D insufficiency and deficiency in children with CKD ranging between 16% and 82% (6,7,9,10).
CKD
Conflicting evidence has been reported regarding a potentially increasing prevalence of vitamin D deficiency with advancing CKD (6,9,28,29) . When adjusting for genetic, environmental, and supplementation variables, we did not observe a major association of renal function 
Vitamin D Supplementation
Patients with vitamin D supplementation had twice as high serum 25(OH)D levels and a 70% lower prevalence of vitamin D deficiency. The positive association of supplementation was independent of age and the severity of renal failure. This observation is in keeping with the results of controlled pediatric trials in children with mild to moderate CKD (7, 30) , whereas previous observational studies, probably because of their smaller sample size, had been unable to link supplementation to vitamin D levels (6, 9, 29) . However, on the background of vitamin D deficiency in 73% of nonsupplemented patients, the overall supplementation rate of 11% seems inappropriately low.
Season and Ethnic Factors
Although lower vitamin D levels during the winter season were expected, the relationship of vitamin D concentrations with the region of origin was surprising. This result prevailed in the multivariate analysis and when only patients without vitamin D supplementation were analyzed. We speculate that cultural factors, such as clothing habits with higher skin cover in girls, and genetic diversity contribute to this finding. Previous studies in Turkish children found sex differences in 25(OH)D levels and associations to concealing clothing in healthy children (31) (32) (33) ). An additional factor may be the slightly darker skin among Turkish patients compared with central European populations, because skin pigmentation has been shown to negatively influence ultraviolet B-induced vitamin D synthesis (34) . In Europe and Turkey, dairy milk products usually are not fortified with vitamin D. Therefore, the main dietary sources of vitamin D are fish products. Surveys of the general population actually show high disparities in the daily fish consumption in Europe and Turkey, with a significantly lower consumption of fish in Turkey (about one third of the consumption in Europe). Southern European countries (e.g., Italy and Greece) are reported to have higher rates of fish consumption compared with northern regions (Germany and The Netherlands) (35, 36) . Although this could further explain the very low vitamin D levels in Turkey, it may play a pivotal role in the explanation of the U-shaped curve of vitamin D levels throughout Europe and Turkey.
Albuminuria and Glomerulopathies
Our observation of the association between glomerulopathies and low 25(OH)D levels confirms the findings of previous studies (6, 29) . Loss of DBP in patients who are proteinuric has been assumed as the likely underlying mechanism (29) . Notably, 24,25(OH) 2 D levels were relatively higher in patients with glomerulopathies and positively correlated with albuminuria. Lower 25(OH)D levels in patients with glomerulopathies may, therefore, partially be explained by more rapid degradation of 25(OH)D secondary to DBP loss and thus, reduced vitamin D binding capacity in patients with gross proteinuria (29) .
24,25(OH) 2 D
We observed strong independent associations of both 25(OH)D and 1,25(OH) 2 D with 24,25(OH) 2 D levels, D (29,37,38) and agonist of CYP24A1, serving to protect the organism from calcium overload (39) . However, in the literature, evidence is not consistent in this regard (40) .
Finally, although 25(OH)D levels were largely independent of eGFR, we noted an independent association of borderline significance of 24,25(OH) 2 D with eGFR, similar to observations in both the pediatric and adult CKD population (29, 41) .
Genetic Influence
We systematically studied the role of common genetic variants on vitamin D status in our pediatric CKD cohort. Common variants in GC are associated with lower DBP serum levels in the general population (16, 42, 43) . In this cohort, only a weak association of lower 25(OH)D levels and higher 24,25(OH) 2 D with a polymorphism in the GC gene was found.
Additional polymorphisms (e.g., in genes involved in cholesterol synthesis or hydroxylation of vitamin D metabolites) have been associated with vitamin D deficiency (15, 24) . However, contrary to these findings in healthy cohorts, we could not verify the influence of the described polymorphisms in our cohort. This may partly be attributed to the fact that our cohort was an ethnically rather homogenous group, and differences were not sufficiently great to detect genetic variabilities. We hypothesize that, in this cohort, environmental and diseaseassociated factors are more relevant in a cohort of CKD and may render negligible the influence of small genetic variations.
Although the large cohort assessed in a wide geographic area and the first exploration of the role of common genetic variants on vitamin D metabolism in pediatric CKD are the most important strengths of this study, our work is limited by its cross-sectional, descriptive character, which precludes demonstration of cause and effect relationships. Also, in the absence of DBP measurements, we can only speculate about genotype-dependent quantitative and/or qualitative differences in DBP and their effects on vitamin D status in children with different types of kidney disease and stages of CKD. Because the participants of this study were mainly white, the results should not be generalized to other ethnic groups, although our data warrant further investigation in other ethnic populations.
In conclusion, we present a unique comprehensive study describing the vitamin D status and its correlates in children with CKD. Vitamin D deficiency is widespread in European children with CKD, and current supplementation practices are only partially efficient in repleting vitamin D stores. Vitamin D levels are influenced by a complex interplay of environmental, disease-and treatment-associated, and ethnic and genetic factors. Vitamin D levels should be monitored, and supplementation practices should be reviewed and adapted accordingly.
